The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, Bydureon) did not slow Parkinson's disease progression or improve symptoms, the phase III Exenatide-PD3 trial showed.

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other conditions with newer weight-loss drugs.

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s disease.

I wouldn’t do another study like this unless you learn what is the target,” Dr. David Standaert, a Parkinson’s researcher at the University of Alabama at Birmingham, told